Page 43 - THE EVOLUTION OF EARLY ARTHRITIS AND CARDIOVASCULAR RISK Samina A. Turk

PREDICTION OF FUTURE RHEUMATOID ARTHRITIS
135.Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against 2 cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis
Res Ther 2011;13(1):R13.
136.Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthri- tis in the preclinical phase? Arthritis Rheum 2003;48(10):2701–5.
137.Nielen MM, van SD, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50(2):380–6.
138.Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinat- ed peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48(10):2741–9.
139.Saraux A, Berthelot JM, Chales G, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002;47(2):155–65.
140.Scofield RH. Autoantibodies as predictors of disease. Lancet 2004;363(9420): 1544–6. 141.Koivula MK, Heliovaara M, Rissanen H, et al. Antibodies binding to citrullinated telo- peptides of type I and type II collagens and to mutated citrullinated vimentin syner- gistically predict the development of seropositive rheumatoid arthritis. Ann Rheum Dis
2012;71(10):1666–70.
142.Nielsen SF, Bojesen SE, Schnohr P, et al. Elevated rheumatoid factor and long term risk of
rheumatoid arthritis: a prospective cohort study. BMJ 2012;345:e5244.
143.van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anticitrullinat- ed protein antibody repertoire is associated with arthritis development in patients with
seropositive arthralgia. Ann Rheum Dis 2011;70(1):128–33.
144.Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is
strongly associated with anti-citrullinated protein antibody status: a prospective cohort
study. Ann Rheum Dis 2010;69(3):490–4.
145.van de Stadt LA, Witte BI, Bos WH, et al. A prediction rule for the development of arthritis
in seropositive arthralgia patients. Ann Rheum Dis 2013;72(12):1920–6.
146.Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodies are pres- ent in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis
Rheum 2013;65(4):911–5.
147.Kolfenbach JR, Deane KD, Derber LA, et al. Autoimmunity to peptidyl arginine deiminase
type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 2010;62(9):2633–
9.
148.Aho K, Palosuo T, Knekt P, et al. Serum C-reactive protein does not predict rheumatoid
arthritis. J Rheumatol 2000;27(5):1136–8.
149.Barra L, Summers K, Bell D, et al. Serum cytokine profile of unaffected first-degree rela-
tives of patients with rheumatoid arthritis. J Rheumatol 2014;41(2):280–5.
150.Deane KD, O’Donnell CI, Hueber W, et al. The number of elevated cytokines and chemo- kines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an
age-dependent manner. Arthritis Rheum 2010;62(11):3161–72.
151.Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clin Exp
Immunol 2006;143(1):1–5.
41